Abstract Purpose of Review This review explores the rationale and available evidence behind incretin-based therapies for metabolic dysfunction-associated steatotic disease (MASLD) and metabolic-associated steatohepatitis (MASH), focusing on glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptor dual agonists (GLP-1/GCG RAs)
If you experience significant nausea or inability to eat during concurrent treatment, contact your provider, as dose adjustments or a brief semaglutide pause may help
Another may sleep eight hours and still feel drained
Other exclusion criteria were treatment with an SGLT-2I, GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP4-I) within 30 days before randomisation, a cardio- or cerebrovascular event within the last 90 days or planned revascularisation
Moreover, few studies have investigated off-target activation in normal tissues where GSH levels may still be substantial (e.g., liver, kidney)